PharmacoEconomics & Outcomes News 792, p3 - 2 Dec 2017 ICER releases draft report on voretigene neparvovec The US Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report on the effectiveness and value of voretigene neparvovec for blindness due to biallelic RPE65-mediated inherited retinal disease. This Draft Evidence Report and asssociated Draft Voting Questions will be open for public comment from stakeholders until 13 December 2017. Comments received will be incorporated into the Evidence Report and Revised Voting Questions that ICER expects to post on 11 January 2018. The Evidence Report will then be discussed and voted on at a public meeting of the Midwest CEPAC on 25 January 2018. * Comparative Effectiveness Public Advisory Council Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Releases Draft Evidence Report on Voretigene Neparvovec, Gene Therapy for Blindness Internet Document : 14 Nov 2017. Available from: URL: https://icer- review.org/announcements/voretigene-draft-report/ 803283334 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud